The global market for Aortic Endografts is expected to grow significantly between 2025 and 2035. This growth is fueled by the rising number of aortic aneurysm cases, advancements in less invasive surgical techniques, and an increasing elderly population. Aortic endografts are an integral part of EVAR and TEVAR procedures, allowing for less invasive methods than open surgical alternatives. Innovation like simplified delivery systems, bespoke endografts and refined graft material are driving demand.
The industry is being fueled by increasing preference for minimally invasive surgical equipment and the enhancement of healthcare systems in developed nations with health insurance policies supporting the devices. At the same time, increasing prevalence of lifestyle diseases such as hypertension, obesity, and smoking related vascular disorders are producing a higher demand for effective aortic aneurysm treatments.
But there are some challenges, including high procedural costs, the risk of complications with the devices, and strict regulatory requirements that could hinder growth. Nonetheless, ongoing research and development, application of AI for exact graft positioning, and rising awareness of patients and healthcare professionals are projected to drive industry growth. It is expected to grow at a CAGR of 4.9% and reach a industry size of USD 5,783.7 million by 2035.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 3,598.4 million |
| Industry Value (2035F) | USD 5,783.7 million |
| CAGR (2025 to 2035) | 4.9% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Given the established healthcare system of North America, the country will most likely secure an intensive share in the aortic endograft industry because of its high adoption of endovascular procedures, and rising trend of aortic aneurysms. The presence of already established players, strong R&D investments, and favorable reimbursement structures further escalate the industry growth.
Moreover, the increasing awareness regarding the early detection and intervention further enriches the surging adoption rates of aortic endografts. But because of the high cost spent on getting approvals and potential risks of complications may present as a challenge in region expansion. Over the forthcoming years, efforts to stabilize regulatory consents and minimize device-associated risks through innovative product development are expected to sustain growth.
Europe is poised to experience a steady growth in the aortic endograft region backed up by the surging healthcare expenditure, an aging population, and spurring requirements for minimally invasive vascular procedures. Leading countries including Germany, the UK, and France are the forefront of incorporating innovative endograft technologies. While the rigorous regulatory polices whose core focus in patient safety may slow down product launches but ensure premium-quality standards.
Furthermore, the efforts done by European governments to refine vascular disease management and early diagnosis programs are projected to foster industrial growth. With the rising demands of already existing specialized training programs for endovascular surgeons, the procedural success rates will surge strengthening the scope aortic endograft applications among patients from different regions.
The Asia-Pacific region is expected to register a growing trend due to the high investments in healthcare, increase in aortic aneurysm cases and improving awareness regarding endovascular repair techniques. Government support for advanced medical treatments and better access to health care in countries like China, India, and Japan are driving the increasing adoption of aortic endografts. In addition to that, the rise in the cases of heart diseases and the increasing preference for minimally invasive procedures are also expected to boost growth.
In developing nations where affordability is a key topic of discussion, the high ranging prices of aortic endograft procedures and devices present a major hindrance. Moreover, device-related complications like graft migration, long-lasting durability issues, endoleaks poses concerns about patient safety and treatment success. What further hinders the industrial innovation and entry is the rigid regulations and lengthy approval processes.
Another major challenge that slows down the industry is limited access to specialized endovascular surgical training and requirements of high-end imaging systems that provide concise graft placement. As there are many alternatives treatment options available like open surgical repair eventually leading to limited adoption of endovascular solution in various patient groups.
Working on these challenges also require high investment in clinical research, consistent developments in technologies and improved training programs that will help in enhancing device performance and safety.
The key contributors in the sector growth of aortic endografts are continuous reforms in technologies of endograft designs featuring bioresorbable materials, smart stent grafts with real-time monitoring capabilities, and AI-assisted imaging techniques. The increasing trend of hybrid operating rooms in hospitals and the spurring incorporation of personalized treatment approached also drive the sector demand.
Emerging sectors for aortic endograft manufacturers are an attractive opportunity, as such manufacturers are often able to offer low-cost alternatives for an important repair of this nature such as an aortic aneurysm. The enhanced nod from administration for early screening and diagnosis, is expected to enhance ease of access to such medical devices.
Moreover, the new partnerships between medical device companies and healthcare institutions are enriching research and innovation, ultimately opening gateways for upcoming growth opportunities of industry. Overall, these factors are expected to grow the scale of aortic endograft industry in the emerging sectors.
Industry-Specific Highlights
Emerging Trends
During 2020 to 2024, the aortic endograft industry witnessed a consistent upward shift due to its increased occurrence of aortic aneurysms, continuous refinements in endovascular repair techniques, and incorporations of minimally invasive procedures. The rising population of old-age groups and the excessive usage of stent-grafts is further channeling the expansion of market. Technological refinements including fenestrated and branched endografts have enhanced treatment outcomes and patient security.
Looking forward to 2025 to 2035, the industry will be crafted by the constant innovation in graft materials, improved imaging-guided deployment techniques, and wider products of customized endografts. With the rising incorporation of AI-powered surgical planning tools and robotics-assisted procedures, the patient outcomes are coming more precisely.
Comparison Table
| Category | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Regulatory approvals focused on improving safety and efficacy, with region-specific requirements for endograft devices. |
| Technological Advancements | Development of fenestrated and branched endografts to accommodate complex anatomies. |
| Consumer Demand | Increasing adoption of minimally invasive endovascular aneurysm repair (EVAR) due to reduced recovery times and improved outcomes. |
| Market Growth Drivers | Rising prevalence of aortic aneurysms, aging population, and improved surgical techniques driving industry expansion. |
| Sustainability | Limited focus on sustainability, with emphasis on performance and sterility. |
| Supply Chain Dynamics | Supply chain disruptions impacted device availability, with reliance on specialized suppliers for high-precision components. |
| Category | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Stricter global regulations emphasizing long-term safety, durability, and patient-specific customization of endografts. |
| Technological Advancements | AI-driven surgical planning, robotics-assisted deployment, and bioresorbable grafts expected to enhance treatment precision and safety. |
| Consumer Demand | Growing demand for patient-specific and custom-designed endografts, expanding the industry for precision vascular interventions. |
| Market Growth Drivers | Continuous technological evolution, increasing global healthcare investments, and expanding treatment options for high-risk patients. |
| Sustainability | Greater emphasis on eco-friendly materials, recyclable components, and sustainable manufacturing practices in compliance with environmental standards. |
| Supply Chain Dynamics | Strengthening supply chain resilience through localized manufacturing and strategic sourcing partnerships to mitigate risks. |
This is mainly due to a rising number of aortic aneurysms and demand for minimally invasive interventions in the USA endografts industry. The growing number of elderly individuals is associated with an increased prevalence of aortic pathologies, which, in turn, demand efficient treatment strategies.
Additionally, technological innovations in endovascular repair techniques and supporting healthcare infrastructure are some of the additional factors boosting the domain’s growth. EVAR accounted for 75% of procedures, an increase for endovascular approaches and a steady decrease for open surgical repairs. Deployed adjunctive medical devices enable further safety improvements in EVAR, and the continued evolution of next generation stent graft surfaces and architectures is aiding improved procedural success rates and outcomes.
Significant investments in R&D in the USA region also contribute to the development of novel aortic endograft devices. Moreover, growing awareness and screening programs for aortic aneurysms leads are finding diagnosis and treatment, which are expected to increase the region during the above-mentioned forecast period.
Market Growth Factors
Germany is a key region for aortic endografts, owing to the strong healthcare system and high standard of care. The rise in the frequency of aortic aneurysm in tandem with a preference for minimally invasive treatment methods is anticipated to boost the uptake of endovascular procedures.
The availability of innovative aortic endograft solutions is also aided by technological advancements and high emphasis on research and development. With its adult population eligible for routine screening, aortic aneurysms are more likely to be identified in Germany, leading to treatment prior to rupture.
Additionally, the recent collaborations between healthcare providers and region participants, along leading medical device manufacturers are presumed to fuel the growth of the industry. Moreover, favorable reimbursement policies and government support for advanced medical technologies further drive the adoption of aortic endografts in clinical practice.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 4.9% |
The endograft industry sector of India will likely experience a substantial growth, led by the rising extent of aortic aneurysms and also the widespread awareness of minimally invasive treatment alternatives. Major factors accelerating the incorporation of refined medical technologies include upgraded healthcare infrastructure and increased investments in healthcare systems.
The increasing population of middle-class and their access to healthcare facilities further pushes the early disease detection and intervention for aortic diseases. Medical tourism also plays a significant role, as India becomes a destination for affordable and advanced cardiovascular treatments.
Collaborations between domestic and international medical device companies enhance the availability of innovative aortic endograft products in the market. Government initiatives aimed at improving healthcare access and affordability further support industry expansion.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 6.2% |
The main reason of the expansion of endograft region scale in Japan is the country’s advanced healthcare infrastructure, high-end medical norms, and rising number of aging population. Japan’s core focus on early detection of disease and taking preventive measure instantly leads to the higher rate of screening for aortic aneurysms.
As minimally invasive techniques like EVAR lowers the complications of elderly patients and speed up the recovery time as well, this is the reason they are widely adopted in the country. Continuous refinements in endografts, featuring patient-specific designs and bioengineered graft materials, further escalate the industry size and innovation sector. With the initiatives from government’s side that support cardiovascular health and medical device research, the accessibility of cutting-edge treatment alternatives is further refining.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 5.5% |
Abdominal Aortic Grafts: The Leading Player in the Industry with High Incidence of Aneurysms High prevalence of abdominal aortic aneurysms (AAA) has driven massive industry share of abdominal aortic grafts within aortic endograft industry. Such grafts are critical in preventing potentially fatal rupture of an aneurysm, a condition that primarily affects the aging population and people with cardiovascular diseases.
The recent development of minimally invasive approaches, most notably Endovascular Aneurysm Repair (EVAR), have greatly supplemented the use of abdominal aortic grafts. Technological advances in graft design have led to improved flexibility, durability and decreased rates of migration, thus improving patient outcomes.
Moreover, the growing awareness and better screening programs for AAA detection have led to early interventions, which has further increased the demand for such grafts. Additionally, a rise in the availability of FDA and CE approved abdominal aortic grafts by several renowned medical device manufacturers will serve to fuel industry growth throughout the forecast period. Considering this, the demand for abdominal aortic grafts is expected to keep growing due to an increasing aging population and rising risk factors such as smoking and hypertension.
Thoracic Aortic Graft Market: Growth Scenario Since the last couple of decades, the use of the aortic endograft has been expanded to involve complex repairs of TAA. These grafts are critical to preventing fatal ruptures of the aorta and are commonly used in open and endovascular approaches. With technological improvements in hybrid grafts and branched stent-grafts the treatment options for complex thoracic anatomies have improved.
The move to low/minimal invasive thoracic endovascular aortic repair (TEVAR) has also contributed to the growth, as this option accelerates recovery time and has lower surgical risks than open surgery. On the analysis based on the end use segment, it is being observed that the segment is expanding due to the rising adoption in aging populations as well as increase in screening for aortic pathologies. Moreover, government efforts to improve healthcare infrastructure and the increasing adoption of advanced medical imaging techniques are encouraging the growth of thoracic aortic graft market.
Endovascular Aneurysm Repair (EVAR): Endovascular Aneurysm Repair (EVAR) is getting widespread recognition as a process of restoring blood flow to the lower body in comparison to earlier used open surgical repair. EVAR has several advantages over traditional open surgical repairs, including decreased recovery time and decreased perioperative morbidity and mortality.
Globally, the use of EVAR has increased significantly owing to technological developments in catheters-based interventions and imaging-guided placement procedures Furthermore, the development of fenestrated and branched endografts has broadened the scope of EVAR for complex aortic anatomies, thus propelling industry growth.
Post-approval clinical data supporting the long-term efficacy and durability of EVAR has driven its broad adoption in both abdominal and thoracic aortic aneurysms. EVAR is favored by healthcare providers and hospitals since it is cost-effective and shortens hospital stays. In the meantime, ongoing studies will assist in increasing the flexibility, biocompatibility, and durability of grafts, further supporting the growth of this segment of the aortic endograft segment and retaining its status as the leading procedure in aortic endograft industry.
Despite the minimisation of the technique, open surgical repair has still become relevant in patients with more complex aortic anatomies not amenable to EVAR. In cases of highly tortuous arteries, huge aneurysms that can be repaired and complications (like ruptured aneurysms), an open procedure is often mandatory.
Although the procedure is more invasive and carries a longer recovery time, it is the gold standard for durability and long-term success in particular patient population. The approach to repair, particularly hybrid techniques that integrate open with endovascular procedures, is the true measure of improved patient outcomes.
Furthermore, in some areas which do not have access to endovascular technology, open surgical repair is still important. Fellowships for vascular surgeons and better perioperative management are anticipated
The Aortic Endograft industry is experiencing substantial growth due to the increasing prevalence of aortic aneurysms, advancements in minimally invasive surgical techniques, and rising adoption of endovascular repair procedures. Key players are focusing on product innovation, regulatory approvals, and strategic partnerships to enhance their industry position. The industry consists of leading medical device manufacturers developing high-quality endografts that offer better patient outcomes and procedural efficiency.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Medtronic plc | 30-35% |
| Cook Medical | 20-25% |
| W. L. Gore & Associates | 15 to 20% |
| Terumo Corporation | 8-12% |
| Other Companies (combined) | 20-30% |
| Company Name | Key Offerings/Activities |
|---|---|
| Medtronic plc | Offers a wide range of aortic endografts, including innovative stent graft systems. |
| Cook Medical | Specializes in advanced endovascular repair devices for abdominal and thoracic aneurysms. |
| W. L. Gore & Associates | Develops highly durable and flexible endografts with advanced sealing technology. |
| Terumo Corporation | Focuses on minimally invasive endograft solutions with a strong global presence. |
Key Company Insights
Medtronic plc (30-35%)
Medtronic is the leader in the aortic endograft industry, with a complete portfolio of stent graft systems for the treatment of aortic aneurysms. Focus on R&D, clinical trials and regulatory approvals helps the company stay competitive in the industry.
Cook Medical (20-25%)
Cook Medical is a leading provider of innovative endovascular repair solutions for both abdominal and thoracic aortic aneurysms. The company is known for its versatility and efficacy of its graft systems, with long-term durability and improved patient outcomes.
W. L. Gore & Associates (15 to 20%)
Known for its advanced endografts with improved flexibility and sealing properties, W. L. Gore & Associates The emphasis for the company is on procedural efficiency, as well as expanding its vascular repair footprint worldwide.
Terumo Corporation (8-12%)
Some of the major players in the global aortic endograft are Terumo Corporation (India) is continuing to expand within aortic endograft industry following their sale of less invasive solutions with advanced delivery systems. The company's growth strategies, impressive R&D investments lead to widening industry presence.
Several other medical device companies contribute to the aortic endograft industry by introducing innovative designs and expanding their geographic reach. Notable players include:
These companies focus on next-generation endograft technologies, patient-specific solutions, and partnerships with healthcare providers to enhance the adoption of endovascular repair procedures. As competition intensifies, innovation and strategic collaborations will be crucial in sustaining industry leadership.
Abdominal Aortic Grafts, Thoracic Aortic Grafts
Metallic Endografts, Stainless Steel, Nitinol, Polymeric Endografts, Dacron, ePTFE
Open Surgical Repair, Endovascular Aneurysm Repair (EVAR), Standard EVAR, Fenestrated EVAR, Branched EVAR, TEVAR, Iliac branched EVAR, Chimney EVAR, Hybrid EVAR
Hospitals, Private Hospitals, Public Hospitals, Ambulatory Surgical Centers
Aortic endografts are stent grafts used in EVAR and TEVAR procedures to treat aortic aneurysms by reinforcing weakened artery walls through minimally invasive surgery.
Key factors include rising aortic aneurysm cases, advancements in graft technology, increasing preference for minimally invasive surgery, and strong healthcare investments.
Challenges include high costs, strict regulatory approvals, device complications (migration, endoleaks), and limited specialist availability.
Trends include AI-driven imaging, bioresorbable stents, outpatient EVAR procedures, and expansion in emerging markets.
| Estimated Size, 2024 | USD 2,861.0 million |
|---|---|
| Projected Size, 2034 | USD 5,436.8 million |
| Value-based CAGR (2024 to 2034) | 6.6% |
| Market CAGR (2023 to 2033) | 3.4% |
|---|---|
| Market Size (2023) | USD 199.3 million |
| Market Size (2033) | USD 278.9 million |
Explore Therapeutic Device Insights
View Reports
Aortic Endograft Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
